Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | DGKA | P23743 | 2/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 2/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32685078 | 0.96 | MGLL (0.66) | MGLLEPHX2DGKACNR2ALDH1A1 | |
| SCHEMBL24728798 | 0.95 | MGLL (0.54) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL24728761 | 0.95 | MGLL (0.59) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL24728757 | 0.94 | MGLL (0.53) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL15939615 | 0.93 | MGLL (0.60) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL15939618 | 0.93 | MGLL (0.60) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL31534465 | 0.92 | MGLL (0.59) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL31534406 | 0.92 | MGLL (0.59) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL4340654 | 0.92 | MGLL (0.62) | MGLLEPHX2DGKADNM1CNR2 | |
| SCHEMBL28424646 | 0.92 | MGLL (0.62) | MGLLEPHX2DGKADNM1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
| EP-3538515-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | Ramot at Tel-Aviv University Ltd. (IL) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087753-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018087753-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292130-A1 | CATIONIC LIPIDS FOR NUCLEIC ACID DELIVERY AND PREPARATION THEREOF | NPC1L1, NPC1, CETP | MGLL 138/4885EPHX2 2483/4885DGKA 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.